Sanofi(US:SNY) GlobeNewswire News Room·2025-02-22 07:30Core Insights - The article discusses the promising results of the RELIEVE UCCD phase 2b study for duvakitug, a monoclonal antibody targeting TL1A, in treating moderate-to-severe ulcerative colitis (UC) and Crohn's disease (CD) [1][6]. Group 1: Ulcerative Colitis (UC) Findings - In the UC cohort, 36% of patients on the 450 mg dose and 48% on the 900 mg dose achieved clinical remission at week 14, compared to 20% on placebo, with placebo-adjusted rates of 16% and 27% respectively [2][6]. - Higher clinical remission rates were noted in both advanced therapy (AT)-experienced and AT-naïve subgroups treated with duvakitug [3][6]. - Additional endpoints showed clinical response rates of 81% for the 450 mg dose and 70% for the 900 mg dose, compared to 52% for placebo [7]. Group 2: Crohn's Disease (CD) Findings - In the CD cohort, 26% of patients on the 450 mg dose and 48% on the 900 mg dose achieved endoscopic response at week 14, compared to 13% on placebo, with placebo-adjusted rates of 13% and 35% respectively [5][6]. - Endoscopic response rates were also higher in both AT-experienced and AT-naïve subgroups treated with duvakitug [5][8]. - Clinical response rates were reported at 61% for the 450 mg dose and 62% for the 900 mg dose, compared to 41% for placebo [15]. Group 3: Safety and Tolerability - Duvakitug was generally well tolerated in both UC and CD cohorts, with no emergent safety signals or dose-dependent adverse events observed [9][6]. - The study's design allowed for a comprehensive evaluation of efficacy and safety across various patient subgroups [11][6]. Group 4: Future Development - The findings from the RELIEVE UCCD study are expected to form the basis for a phase 3 program anticipated to start in the second half of 2025 [6][1]. - The collaboration between Teva and Sanofi aims to co-develop and co-commercialize duvakitug, sharing development costs and profits in major markets [17][1].